Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Current therapeutic protocols for adult ALL consider MRD together with the baseline risk
factors (age, WBC count, immunophenotype, cytogenetics) and speed in response to therapy for
treatment decisions. On the other hand, the systematic use of allogeneic SCT for all adult
patients (pts) with Ph- HR-ALL is still a matter of debate. The aim of the prospective study
ALL-AR-03 from the Spanish PETHEMA Group was to evaluate the response to a differentiated
therapy (chemotherapy or allogeneic SCT) according to early bone marrow blast clearance and
MRD levels (assessed by cytofluorometry at the end of induction and consolidation therapy) in
HR Ph- adult ALL patients.